Diffusion Pharmaceuticals Inc.

Informe acción NasdaqCM:DFFN

Capitalización de mercado: US$13.5m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Diffusion Pharmaceuticals Dirección

Dirección controles de criterios 3/4

Diffusion Pharmaceuticals' CEO is Bob Cobuzzi, appointed in Sep 2020, they has a tenure of 2.92 years. Their total yearly compensation is $691.79K , comprised of 65% salary and 35% bonuses, including company stock and options. They directly owns 0.079% of the company’s shares, worth $10.66K. The average tenure of the management team and the board of directors is 4.9 years and 1.8 years respectively.

Información clave

Bob Cobuzzi

Chief Executive Officer (CEO)

US$691.8k

Compensación total

Porcentaje del salario del CEO65.0%
Permanencia del CEO2.9yrs
Participación del CEO0.08%
Permanencia media de la dirección4.9yrs
Promedio de permanencia en la Junta Directiva1.8yrs

Actualizaciones recientes de la dirección

Recent updates

Diffusion Pharmaceuticals GAAP EPS of -$2.06 misses by $0.02

Aug 12

We Think Diffusion Pharmaceuticals (NASDAQ:DFFN) Needs To Drive Business Growth Carefully

Feb 25
We Think Diffusion Pharmaceuticals (NASDAQ:DFFN) Needs To Drive Business Growth Carefully

Companies Like Diffusion Pharmaceuticals (NASDAQ:DFFN) Are In A Position To Invest In Growth

Nov 12
Companies Like Diffusion Pharmaceuticals (NASDAQ:DFFN) Are In A Position To Invest In Growth

We're Not Very Worried About Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Rate

Jun 25
We're Not Very Worried About Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Rate

Diffusion Pharmaceuticals EPS misses by $0.02

May 10

We're Hopeful That Diffusion Pharmaceuticals (NASDAQ:DFFN) Will Use Its Cash Wisely

Mar 08
We're Hopeful That Diffusion Pharmaceuticals (NASDAQ:DFFN) Will Use Its Cash Wisely

Here's Why We're Watching Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Situation

Nov 23
Here's Why We're Watching Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Situation

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Bob Cobuzzi en comparación con los beneficios de Diffusion Pharmaceuticals?
FechaCompensación totalSalarioIngresos de la empresa
Jun 30 2023n/an/a

-US$13m

Mar 31 2023n/an/a

-US$15m

Dec 31 2022US$692kUS$450k

-US$16m

Sep 30 2022n/an/a

-US$15m

Jun 30 2022n/an/a

-US$24m

Mar 31 2022n/an/a

-US$24m

Dec 31 2021US$783kUS$410k

-US$24m

Sep 30 2021n/an/a

-US$25m

Jun 30 2021n/an/a

-US$17m

Mar 31 2021n/an/a

-US$18m

Dec 31 2020US$1mUS$129k

-US$16m

Compensación vs. Mercado: Bob's total compensation ($USD691.79K) is about average for companies of similar size in the US market ($USD762.43K).

Compensación vs. Ingresos: Bob's compensation has been consistent with company performance over the past year.

CEO

Bob Cobuzzi (58 yo)

2.9yrs

Permanencia

US$691,787

Compensación

Dr. Robert J. Cobuzzi, Jr., also known as Bob, Ph D., serves as its President & Chief Executive Officer at Diffusion Pharmaceuticals Inc. since September 8, 2020 served as its Independent Director since Ja...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Robert Cobuzzi
President & CEO2.9yrsUS$691.79k0.079%
$ 10.7k
William Elder
General Counsel & Corporate Secretary2.9yrsUS$413.92k0.020%
$ 2.6k
David Jones
Senior Medical Advisor10.9yrssin datossin datos
Harry Cook
Vice President of Clinical Operations6.9yrssin datossin datos
Douglas Gravatt
Senior Consultant for Manufacturingno datasin datossin datos
Brian Bollwage
Senior Consultant - Regulatory Affairsno datasin datossin datos

4.9yrs

Permanencia media

58yo

Promedio de edad

Equipo directivo experimentado: DFFN's management team is considered experienced (4.9 years average tenure).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Alan Levin
Independent Director7.6yrsUS$59.00k0.0016%
$ 218.1
Jane Hollingsworth
Independent Chairman2.9yrsUS$77.50k0.060%
$ 8.1k
Mark Giles
Lead Independent Director7.6yrsUS$55.50k0.053%
$ 7.1k
Lakhmir Chawla
Member of Scientific Advisory Boardno datasin datossin datos
Robert Adams
Independent Director7.6yrsUS$54.00k0.0035%
$ 468.6
Timothy A. Yap
Member of Scientific Advisory Board1.5yrssin datossin datos
Mitesh Borad
Member of Scientific Advisory Board1.5yrssin datossin datos
Diana Lanchoney
Independent Director2.2yrsUS$49.00k0.014%
$ 1.9k
Robert Lustig
Member of Scientific Advisory Board1.5yrssin datossin datos
Chad Tang
Member of Scientific Advisory Board1.5yrssin datossin datos
Cullen Taniguchi
Member of Scientific Advisory Board1.5yrssin datossin datos
Michael Harper
Member of Scientific Advisory Boardno datasin datossin datos

1.8yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: DFFN's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.